Identification of targets and new developments in the treatment of multiple sclerosis-focus on cladribine

16Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

Abstract

Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribine, are discussed and balanced with known and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place of this drug in treatment algorithms for MS in the future. © 2010 Warnke et al, publisher and licensee Dove Medical Press Ltd.

Cite

CITATION STYLE

APA

Warnke, C., Wiendl, H., Hartung, H. P., Stüve, O., & Kieseier, B. C. (2010). Identification of targets and new developments in the treatment of multiple sclerosis-focus on cladribine. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s6627

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free